Navigation Links
Anthera Announces Third Quarter 2011 Financial Report and Conference Call
Date:10/24/2011

HAYWARD, Calif., Oct. 24, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will release its third quarter 2011 financial report and provide an update on its development programs after market close on Tuesday, November 1, 2011.  Anthera will host a conference call at 5 pm Eastern Time in conjunction with the release.Conference Call Access:Date:

November 1, 2011Time:

5:00 pm Eastern TimeDomestic Dial-in:

(877) 312-8807International Dial-in:

(253) 237-1190Conference ID:

22066672To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 22066672. The audio replay will be available until November 8, 2011.  

About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.  Anthera has three late stage clinical products: varespladib methyl (A-002), A-001 and blisibimod (A-623).  Varespladib methyl (A-002) and A-001 are designed to inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA2).  Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease.  Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF), which have been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus) and rheumatoid arthritis.  

CONTACT: Bianca Nery of An
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
2. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
3. Anthera Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results and Operational Update
4. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
6. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
7. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
8. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
9. Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
10. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
11. Omega Protein Announces Retention of Lipid Technologies, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 July 29, ... pioneer in the biotechnology industry, announced that it ... Securities, Inc. to explore financing opportunities that build ... a breakthrough vaccine platform with the potential to ... company exclusively licensed the well-established LAMP platform from ...
(Date:7/29/2014)... Tenn. (PRWEB) July 29, 2014 ... in biomass feedstock supply innovation and supply chain ... proprietary feedstock management systems, Energy Grangeā„¢ and Supply ... of R&D and in-the-field testing aimed at consolidating ... offering benefits to landowners, farmers and feedstock end ...
(Date:7/29/2014)... Hill, South Carolina (PRWEB) July 29, 2014 ... with teams of people where cell phone masts or other ... iPhones up to 100 feet away without the need for ... to target longer ranges. , The new app has launched ... of US homes are at very high risk of being ...
(Date:7/29/2014)... Md., July 29, 2014  United Therapeutics Corporation ... its financial results for the second quarter ... growth shows that our medicines are reaching ... arterial hypertension (PAH)," said Martine Rothblatt, Ph.D., ... "The commercial launch this quarter of our ...
Breaking Biology Technology:Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4DisasterTalk App Could Save Lives as Report Reveals 8% of US Homes at Very High Risk of Natural Disaster 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13
... applications based on nanoimprinting techniques (NIL) is evolving at a ... overcome in order to reach the market? How do we ... the industry? What are the tools needed for each product? ... topic, i.e. Nanopatterning, Production and Applications based on Nanoimprinting Lithography. ...
... SEATTLE, April 20, 2012 Cell Therapeutics, Inc. ("CTI" or ... and recent accomplishments for the first quarter of 2012. ... March 31, 2012, total operating expenses were $18.1 million compared ... loss attributable to common shareholders decreased 66% to $17.4 million ...
...  Phigenics LLC, an innovative water management services company, announced ... up to 33% false-positive test results for Legionella ... result means the test indicated Legionella was ... in fact it was below detectable levels at the ...
Cached Biology Technology:Low-cost optical components through nanoimprinting lithography 2Low-cost optical components through nanoimprinting lithography 3Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 2Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 3Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 4Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 5Phigenics Research Challenges Accuracy Of Conventional Legionella Testing Protocol 2Phigenics Research Challenges Accuracy Of Conventional Legionella Testing Protocol 3
(Date:7/29/2014)... of Dentistry (UM SOD) and Medicine (UM SOM) ... five-year $10.7 million grant award from the National ... the National Institutes of Health to study the ... The grant, which renews a previous $12 million ... for the research by studying chlamydial and gonorrheal ...
(Date:7/29/2014)... that brings together two of the major disciplines behind ... insect fossils through stunning photographs and unique illustrations. , ... Jepson, details the incredible preservation and diversity of fossilised ... what these remarkable fossils can tell us about the ... our planet. Like the mosquito in Jurassic Park, many ...
(Date:7/28/2014)... communities showing signs of damage from the Deepwater Horizon oil ... the Gulf of Mexico. The discovery was made by a ... State University. A paper describing this work and additional impacts ... will be published during the last week of July 2014 ... of the National Academy of Sciences . , "The footprint ...
Breaking Biology News(10 mins):University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4Unique images bring fossil insects back to life 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2
... release is available in German . ... as emissions trading, will only be successful if they ... and social issues, says a report published today by ... is formed from seven of the biggest European environmental ...
... Both plant and human diseases that can travel with ... rapidly than has been understood, according to a new ... for some human diseases but also a new fungus ... by scientists at Oregon State University and other institutions, ...
... dancing angels, a research team from the National Institute ... Colorado (CU) has shown how to detect and monitor ... needle point of an atomic force microscope probe, and ... the stability of the instruments measurements under ambient conditions. ...
Cached Biology News:Climate change aims need to be better integrated 2New wheat disease could spread faster than expected 2New wheat disease could spread faster than expected 3Making a point: Picoscale stability in a room-temperature AFM 2
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Anti-Salmonid Ig (H), Alk Phos, (Clone IPA5F12) (mouse IgG2a)...
Rat monoclonal [HK5.3] to B7 RP1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
... with the HECT protein, E6-AP ... Evidence suggests that this E2 ... degradation of non-""N-end rule"" protein ... -acetylated proteins as well as ...
Biology Products: